Cinacalcet in patients on peritoneal dialysis with moderate to severe hyperparathyroidism resistant to conventional treatment. A one-year, prospective study;Cinacalcet en pacientes en diálisis peritoneal con hiperparatiroidismo moderado-severo resistentes a tratamiento convencional. Estudio prospectivo a un año

Nefrologia

Volumn 28, Issue 4, 2008, Pages 419-424

  Portoles J ^a   Tato, A ^a   Lopez Sanchez R ^a   Gruss, E ^a   Cava, F ^a   Ortigosa, A ^a   Molano, Ma D ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Cinacalcet; Clinical guides; Hyperparathirodysm; Open label; Peritoneal dialysis; Target

Indexed keywords

CINACALCET; NAPHTHALENE DERIVATIVE;

ARTICLE; FEMALE; HOSPITALIZATION; HUMAN; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; TIME; TREATMENT FAILURE;

FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; NAPHTHALENES; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 51249097266     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease In CKD: association with mortality In dialysis patients, Am J Kidney Dis 2005; 46 (5): 925-932.
2. Eknoyan G, Levin A, Levin N W, K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease In Chronic Kidney Disease Bone metabolism and disease In chronic kidney disease, Am J Kidney Dis 2003; 42 (S3): 1-2002.
3. Maduell F, Górriz JL, Pallardo LM, Pons R, Santiago C. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients In the community of Valencia. J Nephrol 2005; 18 (6): 739-748.
4. Arenas MD, Álvarez-Ude F, Gil MT, Moledous A, Malek T, Núñez C y cols. Implementation of «K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease In Chronic Kidney Disease» after the Introduction of cinacalcet In a population of patients on chronic haemodlalysls, Nephrol Dial Transplant 2007; 22 (6): 1639-1644.
5. Strlppoll GF, Palmer S, Tong A, Elder G, Messa R Craig JC, Metaanalysis of biochemical and patient-level effects of calcimimetic therapy, Am J Kidney Dis 2006; 47 (5): 715-726.
6. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB y cols, Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16 (3): 800-807.
7. Hutchison JA. Vascular calcification in dialysis patients. Prilozi 2007; 28(1): 215-224.
8. Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A y cols. Grading evidence and recommendations for clinical practice guidelines In nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney lnt 2006; 70 (12): 2058-2065.
9. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K y cols. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int 2006; 69 (11): 1945-1953.
10. Block GA, Raggl P, Bellasi A, Koolenga L, Spiegel DM, Mortality effect of coronary calcification and phosphate binder choice in Incident hemodialysis patients. Kidney Int 2007; 71 (5): 438-441.
11. Block GA, Martin KJ, De Francisco AL, Turner SA, Avram MM, Suranyi MG y cols. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350 (15): 1516-1525.
12. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM y cols, Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006; 1 (2): 305-312.
13. Remón C, Quirós PL, Pérez Bañasco V, Torán D, Tejuca F, Merino MJ y cois, Informe del registra de pacientes con ERC en tratamiento con DP en andalucica: periodo 1999-2004, Nefrologia 2006; 26 (21): 45-55.
14. Cunningham J, Holzer H, Reichel H, Sustained, long-term reductions in parathyroid hormone (IPTH) after 3 years of treatment with the calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SHPT), Nephrol Dial Transplant 2006; 18 (Supl. 4): S150A-S151 A.
15. Salusky IB, Goodman WG: Adynamic renal osteodytrophy: is there a problem? J Am Soc Nephrol 2001; 12: 1978-1985.
16. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Salphoo C y cols, Risk factors for renal osteodystrophy: a multivariant analysis, J Bone Miner Res 1995; 10(1): 149-156.
17. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G y cols, First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl, Kidney Int 2005; 68 (3): 1236-1243.
18. Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP y cols, Bone disease In predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH, Kidney Int 1995; 47 (5): 1434-1442.
19. Quarles LD. Extracellular calcium-sensing receptors In the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003; 12 (4): 349-355.
20. Strlppoll GF, Tong A, Palmer SC, Elder G, Craig JC, Calcimlmetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006; (4): CD006254.
21. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D y cols. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/ Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism, Nephrol Dial Transplant 2005; 20 (7): 1370-1377
22. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J y cols, Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview, Clin J Am Soc Nephrol 2007; 2 (5): 898-905.
23. Narayan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES y cols, Parathyroidectomy versus cinacalcet hydrachloride-based medical therapy In the management of hyperparathyroidism In ESRD: a cost utility analysis, Ami Kidney Dis 2007; 49(6): 801-813.